| dc.description.abstract | Background: COVID-19 is a new infectious disease caused by SARS-CoV-2. Several atypical presentations and extrapulmonary manifestations are also being reported. Extrapulmonary manifestations of COVID-19 include thrombotic events such as pulmonary embolism, acute cerebrovascular attack, myocardial infarction, cardiac arrhythmias, liver damage, gangrene, diarrhea, acute renal failure, rhabdomyolysis and others. Myocardial injury as defined by elevated troponin I has been described in 7.2% to 36% of patients with COVID-19 and is associated with increased mortality. Given this, we are interested in reviewing the relationship between increased troponin I in COVID-19 patients and mortality during treatment at Haji Adam Malik Hospital in Medan.
Aim. To determine the relationship between increased troponin I in COVID-19 patients and mortality during treatment at H. Adam Malik General Hospital Medan.
Methods: This research is a retrospective analytical observational study conducted on COVID-19 patients at H. Adam Malik General Hospital Medan. The bivariate test was carried out using the Fischer Exact test on categorical variables and the Mann Whitney test on numerical variables while the correlation test was carried out using the Spearman correlation test.
Results: This research was conducted at the Integrated Cardiac Center at Haji Adam Malik General Hospital and found that all samples analyzed consisted of 92 included patients. The percentage comparison of COVID-19 patients with increased troponin I had an outcome of 29 patients who died (31.5%) and 13 patients who did not die (14.1%). The percentage comparison of COVID-19 patients without increased troponin I had an outcome of 9 patients who died (9.8%) and 41 patients who did not die (44.6%)
Conclusion: There is a positive strong correlation between patients who have elevated troponin I levels and mortality in COVID-19 patients, and this correlation is a significant correlation. | en_US |
